Catalysts / ANNX
Upcoming FDA decisions and readouts we track for Annexon, each with the filing that announced it.
FreeBioList tracks 4 upcoming catalysts for Annexon (ANNX, listed on Nasdaq). They cover 3 programmes: Tanruprubart (Guillain-Barré syndrome), Vonaprument (Geographic atrophy (Month 15 primary endpoint); Geographic atrophy (Month 24)) and ANX1502 (Cold agglutinin disease).
First on the list: the Regulatory submission for Tanruprubart (Guillain-Barré syndrome), guided by the company to Q4 2026. The furthest-out event tracked is Q3 2027. By stage, the upcoming rows are 1 Phase 2 readout, 2 Phase 3 readouts and 1 Regulatory submission.
All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: NDA vs BLA: the two kinds of US drug application; How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Annexon ANNX · Nasdaq | Tanruprubart | Guillain-Barré syndrome | Q4 2026 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Annexon ANNX · Nasdaq | Vonaprument | Geographic atrophy (Month 15 primary endpoint) | Q4 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Annexon ANNX · Nasdaq | ANX1502 | Cold agglutinin disease | Late 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Annexon ANNX · Nasdaq | Vonaprument | Geographic atrophy (Month 24) | Q3 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList